Skip to content

PTHS PTHS Net product revenues — Total Revenue

Similar metrics at other companies

Geron logo
GERNProduct revenue, net — Total revenues
$51.77M+31.3%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Exelixis logo
EXELNet product revenues — Total revenues
$554.98M+8.1%
Crinetics Pharmaceuticals logo
CRNXProduct revenue, net — Total Revenue
$10.31M
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Aurinia Pharmaceuticals logo
AUPHNet product sales — Revenue
$73.56M+22.7%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's net product revenues — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's net product revenues — total revenue?
PTHS (PTHS) reported net product revenues — total revenue of $10.67M in Q1 2026.
What does net product revenues — total revenue mean?
This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of commercial traction and market adoption for the company's therapeutic portfolio. Tracking this figure allows investors to assess the transition from clinical-stage development to commercial-stage revenue generation.